The Current Ratio as of September 2024 (TTM) for Xencor, Inc. (XNCR) is 6.92

According to Xencor, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.92. This represents a change of -13.80% compared to the average of 8.03 of the last 4 quarters.

Xencor, Inc. (XNCR) Historical Current Ratio (quarterly & annually)

How has XNCR Current Ratio performed in the past?

The mean historical Current Ratio of Xencor, Inc. over the last ten years is 5.86. The current 6.92 Current Ratio has changed 11.71% with respect to the historical average. Over the past ten years (40 quarters), XNCR's Current Ratio was at its highest in in the March 2015 quarter at 21.09. The Current Ratio was at its lowest in in the September 2016 quarter at 1.00.

Xencor, Inc. (XNCR) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Xencor, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Xencor, Inc. (XNCR) Average Current Ratio

How has XNCR Current Ratio performed in the past?

The current Current Ratio of Xencor, Inc. (XNCR) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Xencor, Inc. (XNCR) Current Ratio vs. Peers

How is XNCR’s Current Ratio compared to its peers?

Xencor, Inc.’s Current Ratio is less than Edgewise Therapeutics, Inc. (30.24), less than Keros Therapeutics, Inc. (20.37), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Mineralys Therapeutics, Inc. (11.20), less than Erasca, Inc. (16.79), less than Kura Oncology, Inc. (14.94), less than Protagonist Therapeutics, Inc. (13.73), less than Merus N.V. (9.97), less than Replimune Group, Inc. (13.46), less than Cerevel Therapeutics Holdings, Inc. (10.22), less than IDEAYA Biosciences, Inc. (17.50), less than AnaptysBio, Inc. (9.09), greater than MeiraGTx Holdings plc (2.36), greater than Homology Medicines, Inc. (4.19), less than Nuvalent, Inc. (17.44), less than DICE Therapeutics, Inc. (25.88), greater than Arcellx, Inc. (6.01), less than Vaxcyte, Inc. (17.88), less than Viridian Therapeutics, Inc. (15.82), less than Larimar Therapeutics, Inc. (10.93), less than Syndax Pharmaceuticals, Inc. (10.50), greater than Sutro Biopharma, Inc. (3.41),

Build a custom stock screener for Xencor, Inc. (XNCR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xencor, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xencor, Inc. (XNCR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xencor, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.